Hemotune
Latest round
- Series B
Last raised
- Mar 2024
Total raised
- $23M
Investors
- 7
About Hemotune
Founded in 2017 and based in Zurich, Switzerland, Hemotune AG operates as a biotechnology company. The firm is a spin-off company originating from the Functional Materials Lab at ETH Zurich. The company was founded by its CEO, Lukas Langenegger, and CTO Carlos Mora. Hemotune offers a blood purification platform using magnetic beads to treat conditions like sepsis, infections, and autoimmune diseases by restoring blood balance. The firm’s product line includes a HemoDevice, which is a purification device; HemoDisposable, a sterile single-use disposable tubing set; and HemoSorbent, a single-use product containing tiny magnetic beads.
Who invested in Hemotune
7 investors across 3 rounds
See all investors in Hemotune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hemotune
Who invested in Hemotune?
Hemotune has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hemotune raised?
Hemotune has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Hemotune last raise money?
Hemotune's most recent round on record is a Series B, in Mar 2024.
What does Hemotune do?
Founded in 2017 and based in Zurich, Switzerland, Hemotune AG operates as a biotechnology company.
Where is Hemotune headquartered?
Hemotune is headquartered in Zurich, Switzerland.
Which VCs invest in companies like Hemotune?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Hemotune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Hemotune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.